JP7902113B2 - Il-4rアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 - Google Patents
Il-4rアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法Info
- Publication number
- JP7902113B2 JP7902113B2 JP2022558017A JP2022558017A JP7902113B2 JP 7902113 B2 JP7902113 B2 JP 7902113B2 JP 2022558017 A JP2022558017 A JP 2022558017A JP 2022558017 A JP2022558017 A JP 2022558017A JP 7902113 B2 JP7902113 B2 JP 7902113B2
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- pharmaceutical composition
- composition according
- dose
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001224P | 2020-03-27 | 2020-03-27 | |
| US63/001,224 | 2020-03-27 | ||
| EP21315010.5 | 2021-01-28 | ||
| EP21315010 | 2021-01-28 | ||
| PCT/US2021/024419 WO2021195530A1 (en) | 2020-03-27 | 2021-03-26 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520676A JP2023520676A (ja) | 2023-05-18 |
| JP2023520676A5 JP2023520676A5 (cg-RX-API-DMAC7.html) | 2024-04-03 |
| JP7902113B2 true JP7902113B2 (ja) | 2026-08-07 |
Family
ID=75498103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558017A Active JP7902113B2 (ja) | 2020-03-27 | 2021-03-26 | Il-4rアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230102151A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126951A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7902113B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220158821A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427450A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021244266A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022015363A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173173A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296214A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011730A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021195530A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
| KR102872485B1 (ko) | 2016-09-01 | 2025-10-20 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| JP7736667B2 (ja) | 2019-08-05 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 |
| US20230167171A1 (en) | 2021-08-23 | 2023-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| JP2025501239A (ja) * | 2021-12-30 | 2025-01-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4/il-13アンタゴニストを投与することによってアトピーマーチを減弱する方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505554A (ja) | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2990420T (pt) | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| UA93653C2 (ru) | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
| US7459426B2 (en) * | 2004-06-04 | 2008-12-02 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat autoinflammatory disease |
| CA2664343C (en) | 2006-10-02 | 2016-04-26 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| MX2020012064A (es) * | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| KR102330596B1 (ko) | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
-
2021
- 2021-03-26 KR KR1020227037517A patent/KR20220158821A/ko active Pending
- 2021-03-26 BR BR112022015363A patent/BR112022015363A2/pt unknown
- 2021-03-26 EP EP21718786.3A patent/EP4126951A1/en active Pending
- 2021-03-26 JP JP2022558017A patent/JP7902113B2/ja active Active
- 2021-03-26 IL IL296214A patent/IL296214A/en unknown
- 2021-03-26 AU AU2021244266A patent/AU2021244266A1/en active Pending
- 2021-03-26 MX MX2022011730A patent/MX2022011730A/es unknown
- 2021-03-26 CN CN202180024611.8A patent/CN115427450A/zh active Pending
- 2021-03-26 CA CA3173173A patent/CA3173173A1/en active Pending
- 2021-03-26 WO PCT/US2021/024419 patent/WO2021195530A1/en not_active Ceased
- 2021-03-26 US US17/907,070 patent/US20230102151A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505554A (ja) | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
Non-Patent Citations (2)
| Title |
|---|
| J Am Acad Dermatol,2019年10月10日,vol. 82(2),pp. 407-411 |
| Pediatr Dermatol,2019年,vol. 36(1),pp. 172-176 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230102151A1 (en) | 2023-03-30 |
| CN115427450A (zh) | 2022-12-02 |
| BR112022015363A2 (pt) | 2022-09-20 |
| IL296214A (en) | 2022-11-01 |
| MX2022011730A (es) | 2022-10-13 |
| WO2021195530A1 (en) | 2021-09-30 |
| AU2021244266A1 (en) | 2022-12-01 |
| EP4126951A1 (en) | 2023-02-08 |
| CA3173173A1 (en) | 2021-09-30 |
| KR20220158821A (ko) | 2022-12-01 |
| JP2023520676A (ja) | 2023-05-18 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240322 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250401 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260202 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20260202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260501 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260728 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7902113 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |